XML 66 R53.htm IDEA: XBRL DOCUMENT v3.21.2
DEBT (Details Narrative)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 05, 2021
USD ($)
shares
Aug. 04, 2020
USD ($)
May 12, 2020
USD ($)
May 08, 2020
USD ($)
May 05, 2020
USD ($)
May 12, 2018
USD ($)
May 12, 2017
USD ($)
Aug. 04, 2016
Nov. 19, 2020
USD ($)
Jun. 24, 2020
USD ($)
May 18, 2020
USD ($)
Feb. 25, 2020
USD ($)
Oct. 17, 2018
USD ($)
May 31, 2018
USD ($)
Mar. 31, 2021
shares
Jun. 30, 2021
USD ($)
shares
Jun. 30, 2021
CAD ($)
shares
Jun. 30, 2021
EUR (€)
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
Dec. 20, 2018
Jan. 07, 2021
USD ($)
Oct. 29, 2020
USD ($)
$ / shares
shares
Jul. 03, 2020
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Nov. 16, 2017
USD ($)
Nov. 16, 2015
USD ($)
Loan received from related party     $ 337,110             $ 69,030           $ 355,440     $ (807,795) $ 3,010,000                
Decription of loan payment for interest the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company. The market price at the time this Agreement was negotiated was $3.28 per share   The loan will be repaid in 40 equal monthly instalments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum             the Company received a loan £50,000 ($61,845) from the United Kingdom government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement                                    
Common stock exchange shares | shares 781,819                                                      
Gain on debt extinguisment $ 445,636                                                      
Unpaid interest $ 563,613                                                      
Accrued expenses                               260,347                        
Accrued interest expense                               $ 188,923                        
Restricted shares | shares                             1,800,000                          
Convertible notes payable, principal amount                                           $ 100,000            
Common stock share issued | shares                               16,566,947     15,716,619                  
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales [Member]                                                        
Cash received upon gross sales                                 $ 2,750,000                      
Gross sales                                 $ 13,000,000                      
Equity interest acquired description                               a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services                    
Upfront cash received                                 $ 2,000,000                      
Agreement term                               5 years 5 years 5 years                    
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member]                                                        
Equity interest acquired description                               a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services                    
Upfront cash received                                 $ 2,000,000                      
Agreement term                               5 years 5 years 5 years                    
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales One [Member]                                                        
Cash received upon gross sales                                 $ 2,750,000                      
Gross sales                                 $ 6,500,000                      
Trade Facility [Member]                                                        
Payment of interest and principal                           $ 1,123,600                            
Synthesis facility agreement [Member] | TFF [Member]                                                        
Debt outstanding amount                         $ 5,629,555                              
Accrued expenses                         $ 524,094     $ 402                        
Description for amendment to agreement under ASU 470-50                         The Company evaluated the amended agreement under ASC 470-50 and concluded that it did not meet the 10% cash flow test and recorded debt modification expense of $138,110.                              
Debt modification expense                         $ 138,110                              
Synthesis facility agreement [Member] | TFF [Member] | Principal balance 2 [Member]                                                        
Accrued expenses                               14,800     $ 16,185                  
Notes payable long term                               2,191,880     2,384,850                  
Maturity date                         Aug. 31, 2021                              
Convertible notes payable, principal amount                               2,369,600     2,446,000                  
Debt split, balance                         $ 4,000,000     $ 4,000,000     4,000,000                  
Interest rate description                         6% per annum plus one-month Libor on the USD balance     the Company had accrued $11,250 and $26,231 respectively, in interest expense related to these agreements. the Company had accrued $11,250 and $26,231 respectively, in interest expense related to these agreements. the Company had accrued $11,250 and $26,231 respectively, in interest expense related to these agreements.                    
Repayment of debt, periodic payments                         $ 150,000                              
Frequency of periodic payments                         quarterly                        
Debt Exchange Agreement [Member]                                                        
Debt outstanding amount                 $ 611,500             $ 592,400             $ 2,000,000          
Accrued expenses                               8,856             8,514          
Notes payable long term                 543,557             489,294                        
Convertible notes payable, principal amount                 $ 611,500             2,000,000     2,000,000       $ 1,000,000          
Agreement description                 The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit                                      
Common stock share issued | shares                                             259,741          
Share issued price per share | $ / shares                                             $ 3.85          
Gain on shares                                             $ 192,205          
July 3, 2020 [Member] | Senior Promissory Notes [Member]                                                        
Debt outstanding amount                               $ 5,000,000     5,000,000         $ 5,000,000        
Interest rate                               18.00% 18.00% 18.00%                    
Accrued expenses                               $ 259,149     146,685                  
October 23, 2019 [Member] | Senior Promissory Notes [Member]                                                        
Maturity date                               Oct. 23, 2020 Oct. 23, 2020 Oct. 23, 2020                    
Interest rate                               15.00% 15.00% 15.00%                    
August 4, 2020 [Member] | Senior Promissory Notes [Member]                                                        
Interest rate                               18.00% 18.00% 18.00%                    
Convertible notes payable, principal amount                               $ 3,000,000                        
On April 18, 2018 [Member]                                                        
Libor rate description                               Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate                    
Loan Facility [Member]                                                        
Debt outstanding amount                               $ 3,175,264     3,302,100                  
Notes payable long term                               2,582,864     2,843,475                  
Accrued interest expense                               $ 0     33,021                  
Description of loan repayement                               The Company will make quarterly payments of €125,000 beginning May 6, 2021 with a final payment of €2,200,000 on May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,828,630 of principal and accrued interest of $168,732, or an aggregate of $3,997,362 was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990 The Company will make quarterly payments of €125,000 beginning May 6, 2021 with a final payment of €2,200,000 on May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,828,630 of principal and accrued interest of $168,732, or an aggregate of $3,997,362 was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990 The Company will make quarterly payments of €125,000 beginning May 6, 2021 with a final payment of €2,200,000 on May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,828,630 of principal and accrued interest of $168,732, or an aggregate of $3,997,362 was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990                    
Repayment of debt                               $ 23,696                        
Restricted shares | shares                               1,000,000 1,000,000 1,000,000                    
Bridge Loans [Member]                                                        
Gain on debt extinguisment                                       0                
Marathon [Member]                                                        
Cash received                                       $ 2,000,000                
Grigorios Siokas [Member]                                                        
Interest rate                                         4.70%              
Maturity date                                         Mar. 18, 2019              
Grigorios Siokas [Member] | Senior Promissory Note [Member] | February Note [Member]                                                        
Debt outstanding amount                       $ 1,000,000                                
Interest rate                       18.00%                                
Panagiotis Drakopoulos [Member] | Loan Agreement [Member]                                                        
Debt outstanding amount                               $ 9,784                       $ 9,478
Short term debt borrowing capacity                                                       42,832
Accrued expenses                               $ 7,187                       $ 5,852
Unaffiliated Third Party [Member] | Senior Promissory Notes [Member]                                                        
Debt outstanding amount   $ 3,000,000   $ 2,000,000 $ 2,000,000           $ 2,000,000               $ 2,000,000                  
Loans payable       $ 3,000,000 $ 1,000,000                                              
Description of loan repayment   The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matures on December 31, 2020 unless in default.   The May 8 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 8 Note matured on June 8, 2020. The May 5 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 5 Note matured on December 31, 2020.           The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. The note is not in default and the Company is currently in negotiations with the lender to extend the maturity date.         the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue 261,891 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue 261,891 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue 261,891 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial                    
SkyPharm [Member] | Trade Facility [Member]                                                        
Debt outstanding amount                                                 $ 5,369,678      
Proceeds from debt           $ 247,117                                            
Comodity contract description                               grants more than seventy-five (75) days delay between the payment for products grants more than seventy-five (75) days delay between the payment for products grants more than seventy-five (75) days delay between the payment for products                    
Ownership control                               51.00% 51.00% 51.00%                    
Commitment amount | €                                   € 15,000,000                    
Interest rate description                               (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018 (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018 (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018                    
Facility provided by lender             $ 2,369,600                                          
Facility percentage             95.00%                                          
Originated fee             2.00%                                          
Monthly fee             1.00%                                          
SkyPharm [Member] | Trade Facility [Member] | Minimum [Member]                                                        
Short term debt borrowing capacity                                                     $ 2,291,200  
SkyPharm [Member] | Trade Facility [Member] | Maximum [Member]                                                        
Short term debt borrowing capacity                                                     $ 6,736,200  
SkyPharm [Member] | Loan Facility [Member]                                                        
Interest rate               10.00%                                        
Description for the repayment               No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement as amended is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas.                                        
SkyPharm [Member] | Second amendment to loan facility agreement [Member]                                                        
Short term debt borrowing capacity                                                   $ 70,000